脑胶质瘤免疫治疗研究进展  

Research Progress of Glioma Immunotherapy

作　　者：牟永告[1] MOU Yong-gao(Department of Neurosurgery and Neuro-Oncology,Cancer Center,Sun Yat-sen University//State Key Laboratory of Oncology in South China//Collaborative Innovation Center for Cancer Medicine,Guangzhou,510060,China)

机构地区：[1]中山大学肿瘤防治中心神经外科//华南肿瘤学国家重点实验室//肿瘤医学协同创新中心

出　　处：《中山大学学报（医学版）》2020年第1期24-29,共6页Journal of Sun Yat-Sen University:Medical Sciences

基　　金：国家自然科学基金(81872324);广东省重大科技项目(2015B010125003);广州市科技计划(201704020133);江门市创新团队项目(2018630100110019805)

摘　　要：神经胶质瘤是中枢神经系统中最常见的原发肿瘤,其中过半数是WHOIV级的胶质母细胞瘤,即使接受包括了手术、同步放化疗及辅助化疗的治疗,其中位生存期仍只有14.2个月。免疫抑制是恶性胶质瘤的重要特征,逆转免疫抑制的免疫治疗仍然是近年来最有希望提高胶质瘤患者治疗效果的方式。本文综述了胶质瘤的免疫治疗进展,以及胶质瘤微环境中调节性T细胞(Treg)与糖皮质激素诱导的肿瘤坏死因子受体(G ITR)的研究进展,希望为恶性胶质瘤的免疫治疗提供新的研究思路。Gliomas are the most common primary malignant tumors in the central nervous system,and more than half of them are WHO grade IV glioblastomas.Even if surgery,concurrent chemoradiotherapy and adjuvant chemotherapy were applied,m edian survival of GBM patients is still only 14.2 months.Immunosuppression is an important feature of ma lignant glioma.Immunotherapy which reverse immunosuppression may be the most promising way to improve the treatment effect of glioma patients in recent years.This article reviews the recent progress of glioma immunotherapy and the research progress of regulatory T cells(Treg)and glucocorticoid-induced tumor necrosis factor receptor(G ITR)in the glioma mi croenvironment.We hope this article will provides new research ideas for glioma immunotherapy.

关 键 词：胶质瘤 微环境 调节性T细胞 糖皮质激素诱导的肿瘤坏死因子受体 

分 类 号：R739.41[医药卫生—肿瘤]